\
&
Contact us
\
&
Contact us
Published on | 3 years ago
ProgrammesThe draft versions of the 2023-2024 Work Programmes (WP) of most of the Horizon Europe subprogrammes have been published by the European Commission here.
The General introduction, General Annexes and EU Missions WP can now also be consulted.
The draft work programme of Cluster 3 "Civil Security for Society" is not yet included in this list.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Health Civil Security Digital, Industry & Space Agro-Food, Environment
The European Innovation Council has launched a call to recruit independent experts of diverse innovative defence and dual-use technologies (as eg. maritime, medical, drones, financial expertise, ..). It is important for the EIC to have a solid batch of experts with a balanced national diversity. Note that, as a requirement and due to security sens... read more
Culture and society Climate, Energy, Mobility EIC
OASC (Open & Agile Smart Cities & Communities) is a partner in the ACCEND project, a Europe-wide project building the foundations for a stronger, more connected deep tech scaleup scene. If you're developing solutions for Smart Cities, Net Zero Cities or Regenerative Cites, you might be interested in this opportunity to accelerate your... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
